Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study

Open Access

Peer-reviewed

Research Article

Ariel Hammerman ,

* E-mail: arielha@clalit.org.il

Affiliation Chief Physician’s Office, Clalit Health Services Headquarters, Tel-Aviv, Israel
⨯
Sari Greenberg-Dotan,

Affiliation Chief Physician’s Office, Clalit Health Services Headquarters, Tel-Aviv, Israel
⨯
Ilan Feldhamer,

Affiliation Chief Physician’s Office, Clalit Health Services Headquarters, Tel-Aviv, Israel
⨯
Haim Bitterman,

Affiliations Chief Physician’s Office, Clalit Health Services Headquarters, Tel-Aviv, Israel, The Bruce and Ruth Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel
⨯
Rinat Yerushalmi

Affiliations Institute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
⨯

Reader Comments (0)

Brain metastasis
Is the Subject Area "Brain metastasis" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Hormonal therapy
Is the Subject Area "Hormonal therapy" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Cohort studies
Is the Subject Area "Cohort studies" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Multivariate analysis
Is the Subject Area "Multivariate analysis" applicable to this article?

Thanks for your feedback.